AzTrials
AzTrials

Incomplete Spinal Cord InjuryNCT04050696

The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) Patients

A study testing BQ 1.2 in people with Incomplete Spinal Cord Injury, run by BrainQ Technologies Ltd. at 3 sites in 2 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to further establish safety and efficacy of the BQ EMF treatment of chronic SCI subjects who demonstrate stability in The Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) strength score following a one-month physical therapy run-in period. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Incomplete Spinal Cord Injury
What is being tested?
BQ 1.2
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
3 sitesin 2 countries
Study dates
18 Sep 2019to 1 Feb 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males and non-pregnant females who are between 18 to 75 years of age
  • Diagnosed with traumatic or (incident-related) non-traumatic chronic cervical incomplete SCI (AIS B-D), 12 to 30 months from event.
  • Individuals with a score between 5 - 35 on the GRASSP strength subscore on at least one side
  • Medically stable
  • Cognitive status and ability to communicate must be at a level consistent with that which is required to participate in motor rehabilitation regimen (e.g. can follow directions and cued tasks)
  • Stable pharmacological treatment plan without any planned modifications
Show all 10Show fewer
  • Able to engage in physical therapy program as stipulated per protocol
  • Passive shoulder flexion of at least 60 degrees and passive shoulder abduction of at least 40 degrees, to ensure ability to perform upper limb motor tasks
  • Negative pregnancy test in women of childbearing potential
  • Subject can independently provide consent (written or verbal in the presence of a family member) to participate in the study and is willing to comply with study procedures

Who cannot join

  • Subjects not eligible for this study include those that have any of the following:
  • Excessive pain in the UE that limits the administration of the evaluation measurements
  • Excessive spasticity: subjects with MAS of wrist ≥ 2, or MAS of elbow ≥ 3
  • Received botulinum toxin in the previous 4 months, or planning of an upcoming injection during the trial period
  • Participating in any other experimental rehabilitation or drug studies
  • Medical conditions or circumstances that, in the opinion of the investigators, would preclude safe and/or effective participation
Show all 10Show fewer
  • Severe cognitive or psychiatric problems that might significantly impact the successful study conduct
  • History of epileptic seizures or epilepsy
  • Implanted electronic medical devices
  • Alcoholism or drug addiction as defined by DSM-IV within last 5 years

Trial locations and contacts

3 sites in 2 countries.

3 sites in 2 countries

United States2 sites, 2 recruiting
  • The Miami Project to Cure Paralysis

    Miami, Florida, 33136

    Katie Gant, Ph.D., 305-243-7108, kgant@miami.edu

    Recruiting
  • Kessler Institute of Rehabilitation

    West Orange, New Jersey, 07052

    Ghaith Androwis, Ph.D., 973-324-3565, gandrowis@kesslerfoundation.org

    Recruiting

Other trials in United States

Israel1 site, 1 recruiting
  • Sheba Medical Center

    Ramat Gan

    Adi Estrin, +972 54-448-2357, adi.estrin@gmail.com

    Recruiting

Other trials in Israel

About this study

Official title: The Safety and Efficacy of the Use of a Brain-computer Interface-based Electromagnetic Field Treatment in the Management of Chronic SCI Patients - a Pilot Study

The purpose of this study is to further establish safety and efficacy of the BQ EMF treatment of chronic SCI subjects who demonstrate stability in The Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) strength score following a one-month physical therapy run-in period.

Read the detailed description

BQ is a brain-computer interface (BCI) based medical device that produces and delivers non-invasive, low intensity and low frequency electromagnetic fields targeting a patient's central nervous system (CNS) for motor rehabilitation. The technology behind the device utilizes machine learning (ML) tools to identify high-resolution spectral patterns, which characterize motor functions within EEG and MEG/EMG measurements taken during functional motor tasks. These patterns are then translated into a frequency-dependent, low intensity and non-invasive electromagnetic treatment, which applies similar patterns directly to a patient's CNS.

BQ treatment is intended to improve upper limb motor function of chronic SCI patients, over 18 years of age with an incomplete injury and upper limb motor impairment (AIS B - D, Cervical C1 - C8). The treatment will be administered as an adjunctive treatment along with a typical pharmacological and/or non-pharmacological treatment plan.

Study is a prospective, single arm, multicenter study with physical therapy (PT) run-in phase, where each subject serves as his/her own control. Study population will include at least 8 individuals with traumatic or (incident-related) non-traumatic chronic cervical incomplete SCI (AIS B-D) who are 12 - 30 months post-injury, with score between 5 - 35 on GRASSP strength subscore on at least one side, and medically stable.

The primary objective of this study is to evaluate the efficacy of the BQ system treatment in improving upper limb motor function of chronic SCI subjects, compared to their own baseline after stability has been demonstrated during physical therapy run-in period, as measured by improvement in GRASSP strength subscore. An additional secondary objective of the study is to evaluate the efficacy of the BQ system treatment in improving motor recovery, spasticity, pain, QOL, and imaging outcomes in the stated population.

Being tested
BQ 1.2
Keywords
chronic SCI, incomplete SCI, central cord syndrome, electromagnetic field, physical therapy, cervical SCI, paraplegia, tetraplegia, upper limb impairment, GRASSP, ISNCSCI
Medical subject headings
Central Cord Syndrome, Paraplegia, Quadriplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BQ 1.2Device

    BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen

Study groups in NCT04050696
Study groupRoleWhat they receive
Treatment (with PT run-in)ExperimentalTreatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
Receives: Device: BQ 1.2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline of treatment to end of treatment in the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP - strength subscore):

    The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb.

    The evaluation includes three domains of hand function:

    1. Strength (primary)
    2. Sensibility (secondary)
    3. Prehension (secondary)

    For the primary outcome measure, only the strength subscore will be assessed as follows:

    ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)

    Measured: Week 22

Secondary outcomes (9)
  1. GRASSP (strength subscores)

    The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb.

    ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)

    Measured: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  2. GRASSP (sensibility and prehension subscores)

    For the secondary outcome measure, the sensibility and prehension subscores will be assessed as follows:

    • Dorsal sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12)
    • Palmar sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12)
    • Prehension ability: 3 grasps (cylindrical, lateral key, tip to tip), each scored 0-4 (sum = 0-12).
    • Prehension performance: 6 prehension tasks - pour water from bottle, pick up an object, transfer 9 pegs from board to board, screw four nuts onto bolts, each scored 0-5 (sum = subtest score, 0-30).

    Measured: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  3. ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury)

    This is a system of tests used to define and describe the extent and severity of a subject's spinal cord injury. The subject's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function.

    For the purposes of this study, only the motor subtests and functions (UEMS \& LEMS) will be considered as a secondary outcome measure.

    The full ISNCSCI will be administered and assessed at baseline and end of treatment only for AIS classification purposes.

    Measured: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  4. Modified Ashworth Scale (MAS)

    The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity (Bohannon \& Smith, 1987). Scoring are as follows:

    • 0: No increase in muscle tone
    • 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension
    • 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
    • 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    • 3: Considerable increase in muscle tone, passive movement difficult
    • 4: Affected part(s) rigid in flexion or extension

    Measured: Week -1, week 1, week 5, week 22

  5. Spinal Cord Independence Measure III (SCIM III - self-care sub-score)

    The Spinal Cord Independence Measure (SCIM) is a disability profile containing 3 sub-scales developed specifically for people with spinal cord injury (SCI). Through measures across its distinct scales, the profile describes subjects' ability to undertake activities of daily living (Ackerman, Morrison, McDowell, \& Vazquez, 2010). Each area is scored according to its proportional weight in these subjects' general activity. The final score ranges from 0 to 100 (Ackerman et al., 2010). The SCIM includes the following areas of function:

    • Self-care (sub-score 0 - 20)
    • Respiration and sphincter management (sub-score 0 - 40)
    • Mobility (sub-score 0 - 40)

    Measured: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  6. Questionnaire of von Korff et al. Grading the Severity of Chronic Pain

    This is a simple method of grading the severity of chronic pain. This questionnaire grades the severity of chronic pain based on its characteristics and its impact on a person's activities (Von Korff, Ormel, Keefe, \& Dworkin, 1992).

    Answers are graded on a 0 (no) - 10 (extreme) scale for each of the following questions:

    • Rate pain at present time
    • Rate of most intense pain in the last 6 months
    • Rate of average pain in the last 6 months
    • In the past 6 months, how has pain interfered with your daily activities
    • In the past 6 months, how has pain interfered with your recreational social and family activities
    • In the past 6 months, how has pain interfered with your ability to work

    Measured: Week 1, week 5, week 22

  7. Capabilities of the Upper Extremity Test (CUE-T)

    A 32-item questionnaire with items in seven domains. The CUE test displays excellent test/retest reliability, and excellent correlation with impairment and capacity measures in persons with incomplete SCI. Subjects are scored on a 7-point scale representing self-perceived difficulty: 1 indicating totally limited, can't do at all, and 7 indicating not at all limited. Minimum score is 32 and maximum score is 124 (Marino, Shea, \& Stineman, 1998).

    Subjects will be asked to complete the following tasks:

    • 15 unilateral (left and right) items
    • 2 bilateral items
    • 3 reaching items
    • 4 pulling/pushing items
    • 2 wrist items
    • 6 hand/finger items
    • 2 bilateral items

    Measured: Week 1, week 5, week 22

  8. The Spinal Cord Injury-Quality of Life (SCI-QOL)

    The measurement system was developed to address the shortage and non-uniformity of subject-reported outcome measures for clinical care and research in SCI rehabilitation. It consists of 19 items, measuring emotional health (depression, anxiety, resilience, positive affect and well-being, grief/loss, self-esteem, stigma, psychological trauma); physical-medical health (bowel management, bladder management, bladder complications, pressure ulcers, pain interference, pain behavior); social participation (ability to participate in social roles and activities, satisfaction with social roles and activities, independence); physical function (basic mobility, self-care, fine motor functioning, wheelchair mobility, ambulation) (Tulsky et al., 2015).

    Measured: Week 1, week 5, week 22

  9. Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) scans

    For applicable subjects, MRI scans will be performed, preferably with a 3.0 T Ingenia Philips scanner, according to the follow sequences:

    1. Sagittal T2 B. Sagittal STIR C. Sagittal PW (proton density) D. Sagittal T1 E. Sagittal DTI F. Axial T1 G. Axial T2 MRI results will be analyzed to quantify tissue integrity (e.g. white matter, grey matter, cerebrospinal fluid). DTI measurements will be used to identify water movement, which, in the CNS, is often localized within axons, and provides high contrast towards white matter, indicating the quality and quantity of nerve fibers. This endpoint is not obligatory per protocol; failure to complete in contraindicated subjects is not considered a protocol deviation per Good Clinical Practice.

    Measured: Week 5, week 22

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2019
  2. Study start18 Sep 2019
  3. Primary completion1 Dec 2023 (estimated)
  4. Study completion1 Feb 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
8 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04050696
Sponsor's protocol ID
BQ4
Status last verified
Aug 2023
First submitted
30 Jul 2019
Last updated
22 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: Metadata can be made available, upon reasonable request Individual patient data (IPD) to be shared if significant need/benefit can be demonstrated, and only with permission of individual subject, as it is not specifically covered in informed consent form (ICF)

Questions about this trial

What is this clinical trial studying?

A study testing BQ 1.2 in people with Incomplete Spinal Cord Injury, run by BrainQ Technologies Ltd. at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Assaf Lifshitz (+972-54-4586787, assaf@brainqtech.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline of treatment to end of treatment in the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP - strength subscore): (time frame: Week 22). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2023; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in